

About SynDermix

Founded in 2009, SynDermix AG is a Swiss developer of innovative health technologies funded by private investors. The company focuses on developing ground-breaking therapies that are effective, safe and which meaningfully respect patient convenience, to treat disorders where there is a high unmet medical need.

Vision, mission and values

Our vision: The vision of SynDermix is to deliver breakthrough innovation that addresses patient convenience equally well to efficacy and safety in areas of major unmet medical need.

Our mission: The Company's mission is to enter into strategic partnerships for the acquisition, development and commercialisation of a robust portfolio of assets that are consistent with the vision of SynDermix, and to deliver value to its shareholders.

Values: We are committed to values that we believe foster and sustain successful teamwork and partnerships, to integrity, dedication and fairness. We view continued innovation as the answer to unmet and changing healthcare needs, and consider patient convenience as an equally important aspect (together with efficacy and safety) of the therapies we select for development and commercialisation.

Operating Model

The Company is operating a lean and networked structure, led by seasoned executives with experience in business management, drug development, finance and deal-making. It leverages its strong links to medical Key Opinion Leaders, specialist service providers and major industry players.

Business Model

Our business model is to a large extent virtual, driven by a strategy of in-licensing, outsourcing and out-licensing:

- i) SynDermix acquires or in-licenses novel and commercially attractive assets from academic research hubs and other companies
- ii) The Company outsources product and clinical development to contract service providers, to accomplish registration in the most resource-effective way
- iii) The Company achieves market access and generates cash inflows (from milestone payments and royalties) through deals with relevant industry players.



Konstantinos Efthymiopoulos
PharmD, PhD, MBA

Chairman & Managing Director

Our partners

IP, Regulatory & Corporate

Keltie Intellectual property company, London

DANUBIA Patent & law office, Budapest
PATENT & LAW OFFICE LLC

ARIA Financial and administrative service, Zürich
SERVICES AG - ZÜRICH

manage mind Project management for innovation industries, Zürich

BIHRER RECHTSANWÄLTE AG International & commercial lawyers, Zürich

balmeretienne Tax consulting and audit services, Zürich

BIO SCIENCE VALUATION Biotechnology company valuers & consultants, Garmins
Knowledge and Evidence-based Solutions

Manufacturing

FUJIFILM Biotechnologies manufacturer, Billingham
DiaSynth biotechnologies

creaholic Professional inventors, Biel

Clinical & Non-Clinical

iss Integrated scientific services, Biel
INTEGRATED SCIENTIFIC SERVICES A MEDITECH COMPANY

KING'S COLLEGE LONDON Institute of Pharmaceutical Science KCL, London


Portfolio

Our portfolio includes three asset-centric fully-owned subsidiaries with similar operating models.


BioEleSonic AG: An electronic medical device company based on Precisely Modulated Acoustic Energy™ (PMAE); the company is characterised by the non-invasive application of PMAE that is capable of targeting internal disrupted tissues with accuracy, fast onset of action, efficacy and safety.



Noxogen Therapeutics AG: A platform based on an endogenous nitric oxide (NO) donor in an easy-to-use formulation, which solves the challenges of releasing and stabilising NO locally for therapeutic use.




TheraLect AG: A drug platform based on a novel recombinant plant lectin with positive Phase IIa results in epithelial healing; SynDermix is currently evaluating the most attractive clinical indications that may be targeted with this protein.




To maximise the value of the assets in its portfolio, SynDermix additionally leverages its technologies to drive a wellcare pipeline of consumer health and cosmetic products.

Pipeline

Medical Devices (BioEleSonic)



Drug Candidates (Noxogen Tx & TheraLect)



Contact

SynDermix AG
Buochserstrasse 2
6370 Stans, Switzerland

Website: www.syndermix.ch
Email: info@syndermix.ch

ISIN: CH0121242769

Member of

